New marburg vaccine trial shows promise in early human testing
NCT ID NCT06265012
First seen Sep 30, 2025 · Last updated May 19, 2026 · Updated 29 times
Summary
This early-stage trial tested a new vaccine (PHV01) against Marburg virus, a rare but deadly disease. Thirty-six healthy adults received either the vaccine or a placebo and were monitored for 181 days. The main goals were to check safety and see if the vaccine triggers an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARBURG VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel RCA
Hollywood, Florida, 33024, United States
Conditions
Explore the condition pages connected to this study.